Search Within

Allison Betof Warner

Formats
  1. Meeting Abstract (35)
  2. Journal Article (31)
  3. Review (6)
  4. Correspondence (1)
  5. Editorial (1)
  6. Guidelines (1)
  7. Research Letter (1)
Groups
  1. Department of Medicine (76)
  2. Hematologic Malignancies, Division of (76)
  3. Melanoma and Immunotherapeutics Service (76)
  4. Solid Tumor Oncology Division (76)
  5. Weinberg Fellows (76)
  6. Melanoma Disease Management Team (37)

More Groups

People
  1. Jedd Wolchok (29)
  2. Michael Postow (28)
  3. Alexander Shoushtari (24)
  4. Katherine Panageas (18)
  5. Margaret Callahan (18)
  6. Paul Chapman (17)

More People

Years
  1. 2024 (4)
  2. 2023 (10)
  3. 2022 (15)
  4. 2021 (17)
  5. 2020 (12)
  6. 2019 (5)

More Years

Publications
  1. Journal of Clinical Oncology (19)
  2. Journal for ImmunoTherapy of Cancer (8)
  3. Cancer Research (6)
  4. Clinical Cancer Research (5)
  5. Annals of Oncology (4)
  6. International Journal of Radiation Oncology, Biology, Physics (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (19)
  2. American Association for Cancer Research (11)
  3. Biomed Central Ltd (9)
  4. Elsevier Inc. (9)
  5. Oxford University Press (5)
  6. Wiley Blackwell (4)

More Publishers

Results (76)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply
    Correspondence

    Pires da Silva, I.; Ahmed, T.; Reijers, I. L. M.; Warner, A. B.; Randall Patrinely, J.; Serra-Bellver, P.; Allayous, C.; Mangana, J.; Zimmer, L.; Trojaniello, C.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
    Guidelines

    Guidon, A. C.; Burton, L. B.; Chwalisz, B. K.; Hillis, J.; Schaller, T. H.; Amato, A. A.; Betof Warner, A.; Brastianos, P. K.; Cho, T. A.; Clardy, S. L.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: A multicentre, retrospective, cohort study
    Journal Article

    Pires da Silva, I.; Ahmed, T.; Reijers, I. L. M.; Weppler, A. M.; Betof Warner, A.; Patrinely, J. R.; Serra-Bellver, P.; Allayous, C.; Mangana, J.; Nguyen, K.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Phase II, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumours
    Meeting Abstract

    Gettinger, S.; Kluger, H.; Schoenfeld, A.; Betof Warner, A.; He, K.; Sukari, A.; Thomas, S. S.; de SpeĢville, B. D.; Lee, S.; Haefliger, S.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas
    Journal Article

    Shoushtari, A. N.; Chatila, W. K.; Arora, A.; Sanchez-Vega, F.; Kantheti, H. S.; Rojas Zamalloa, J. A.; Krieger, P.; Callahan, M. K.; Betof Warner, A.; Postow, M. A.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
    Journal Article

    Beattie, J.; Rizvi, H.; Fuentes, P.; Luo, J.; Schoenfeld, A.; Lin, I. H.; Postow, M.; Callahan, M.; Voss, M. H.; Shah, N. J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT)
    Meeting Abstract

    Campbell, M. T.; Zhang, T.; Chin, L.; Warner, A. B.; Mathew, M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II study to evaluate the need for > two doses of nivolumab plus ipilimumab combination (combo) immunotherapy
    Meeting Abstract

    Postow, M. A.; Goldman, D. A.; Shoushtari, A. N.; Warner, A. B.; Callahan, M. K.; Momtaz, P.; Naito, E.; Eton, O.; Nair, S.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • The nature and management of acquired resistance to PD1-based therapy in melanoma
    Meeting Abstract

    Hepner, A.; Versluis, J. M.; Gerard, C. L.; Brown, L. J.; Wallace, R.; Bhave, P.; Jansen, Y.; Klein, O.; Warner, A. B.; Mangana, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy
    Meeting Abstract

    Da Silva, I. P.; Ahmed, T.; Lo, S.; Reijers, I. L. M.; Weppler, A.; Warner, A. B.; Patrinely, J. R.; Serra-Bellver, P.; Lebbe, C.; Mangana, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save